Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of
10.1016/j.apsb.2021.02.012
- Author:
Cláudia Pina COSTA
1
;
João Nuno MOREIRA
2
;
José Manuel SOUSA LOBO
1
;
Ana Catarina SILVA
1
Author Information
1. UCIBIO/REQUIMTE, Medtech, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto 4050-313, Portugal.
2. CNC - Center for Neuroscience and Cell Biology, Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Faculty of Medicine (Pólo I), Coimbra 3004-504, Portugal.
- Publication Type:Review
- Keywords:
Intranasal administration;
In vivo studies;
NLC;
Nanoemulsions;
Nanostructured lipid carriers;
Nose-to-brain delivery;
Pharmacodynamics;
Pharmacokinetic;
SLN;
Solid lipid nanoparticles
- From:
Acta Pharmaceutica Sinica B
2021;11(4):925-940
- CountryChina
- Language:English
-
Abstract:
The management of the central nervous system (CNS) disorders is challenging, due to the need of drugs to cross the blood‒brain barrier (BBB) and reach the brain. Among the various strategies that have been studied to circumvent this challenge, the use of the intranasal route to transport drugs from the nose directly to the brain has been showing promising results. In addition, the encapsulation of the drugs in lipid-based nanocarriers, such as solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs) or nanoemulsions (NEs), can improve nose-to-brain transport by increasing the bioavailability and site-specific delivery. This review provides the state-of-the-art of
